Display options
Cite
Weintraub M, Kalebic T, Helman LJ, et al. Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. Sarcoma. 1997;1(3):135-41doi: 10.1080/13577149778218.
Weintraub, M., Kalebic, T., Helman, L. J., & Bhatia, K. G. (1997). Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. Sarcoma, 1(3), 135-41. https://doi.org/10.1080/13577149778218
Weintraub, M, et al. "Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma." Sarcoma vol. 1,3 (1997): 135-41. doi: https://doi.org/10.1080/13577149778218
Weintraub M, Kalebic T, Helman LJ, Bhatia KG. Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. Sarcoma. 1997;1(3):135-41. doi: 10.1080/13577149778218. PMID: 18521215; PMCID: PMC2395370.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 1997;1(3):135-41. doi: 10.1080/13577149778218.

Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma.

Sarcoma

M Weintraub, T Kalebic, L J Helman, K G Bhatia

Affiliations

  1. Pediatric Branch National Cancer Institute National Institutes of Health Building 10, Room 13N240 Bethesda MD 20892 USA.

PMID: 18521215 PMCID: PMC2395370 DOI: 10.1080/13577149778218

Abstract

Purpose. Rhabdomyosarcoma (RMS) is an embryonal tumor thought to arise from skeletal muscle cells that fail to differentiate terminally. The majority of RMSs express MyoD, a protein essential to the differentiation of skeletal muscle. It was recently shown that during myogenesis, MyoD activates the expression of the cyclin-dependent kinase inhibitor (CDKi), p21, which itself plays a critical role in normal muscle development. To investigate the integrity of the MyoD/p21 pathway in RMS, we analyzed p21 and its relationship to MyoD expression in RMS.Methods. A panel of RMS samples was assembled from primary biopsies and from cell lines. Integrity of p21 was analyzed by single-strand conformation polymorphism (SSCP) and sequencing. Expression of p21 and MyoD was determined by Northern blot analysis, and the ability of exogenous p21 to arrest the cell cycle of RMS cell line was determined by transfection studies.Results. Our analysis indicates that although p21 is wild type in RMS, there is an inverse correlation between the levels of p21 and MyoD in these tumors. Tumors that express significant amounts of MyoD fail to express p21. This does not appear to be the result of mutations within the potential CACGTG sites present in the p21 promoter region or in the coding region of p21. An additional group of RMSs express very high levels of p21 but express little, if any, MyoD. Furthermore, RD, a RMS cell line which expresses high levels of endogenous p21, undergoes withdrawal from the cell cycle following forced expression of p21, suggesting that the pathway which would lead to G(1) arrest from endogenous p21 activity is defective.Discussion. These data suggest that the interaction between p21 and MyoD is defective in RMS although the precise nature of the defect remains to be elucidated.

References

  1. J Clin Invest. 1991 Apr;87(4):1133-8 - PubMed
  2. Mol Cell Biol. 1982 Sep;2(9):1044-51 - PubMed
  3. Blood. 1994 Dec 1;84(11):3781-4 - PubMed
  4. Genes Dev. 1995 May 15;9(10):1149-63 - PubMed
  5. Cancer Res. 1995 Apr 1;55(7):1431-5 - PubMed
  6. Oncogene. 1990 Nov;5(11):1731-3 - PubMed
  7. Science. 1995 Feb 17;267(5200):1022-4 - PubMed
  8. J Clin Invest. 1989 Sep;84(3):829-39 - PubMed
  9. Am J Pathol. 1995 Dec;147(6):1799-810 - PubMed
  10. Genes Dev. 1989 May;3(5):628-40 - PubMed
  11. Adv Cancer Res. 1995;66:181-212 - PubMed
  12. Science. 1995 Feb 17;267(5200):1024-7 - PubMed
  13. Am J Pathol. 1990 Dec;137(6):1283-91 - PubMed
  14. Cell. 1993 Feb 12;72(3):309-24 - PubMed
  15. Cancer. 1969 Sep;24(3):520-6 - PubMed
  16. Cancer Res. 1995 Oct 15;55(20):4536-9 - PubMed
  17. Genes Chromosomes Cancer. 1989 Sep;1(1):23-35 - PubMed
  18. Oncogene. 1995 Feb 2;10(3):599-601 - PubMed
  19. Genes Dev. 1994 Aug 1;8(15):1750-8 - PubMed
  20. Science. 1993 Mar 5;259(5100):1450-3 - PubMed
  21. Oncogene. 1996 May 16;12(10):2155-64 - PubMed
  22. Genomics. 1993 May;16(2):325-32 - PubMed
  23. Cell. 1993 Nov 19;75(4):817-25 - PubMed
  24. Oncogene. 1995 Dec 21;11(12):2609-18 - PubMed
  25. Cancer Res. 1991 Oct 1;51(19):5100-6 - PubMed
  26. Biochemistry. 1979 Nov 27;18(24):5294-9 - PubMed
  27. Science. 1994 Jun 3;264(5164):1467-71 - PubMed
  28. Oncogene. 1994 Oct;9(10):3021-4 - PubMed
  29. J Biochem. 1992 Oct;112(4):427-30 - PubMed
  30. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766-70 - PubMed
  31. Science. 1995 Feb 17;267(5200):1018-21 - PubMed

Publication Types